[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100279446":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":10,"locations":26,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":10,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Rennes University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ECMO piperacillin",null,"patients in intensive care treated with ECMO with antiinfective therapy : piperacillin",[13],"Other: blood sample",{"label":15,"type":10,"description":16,"interventionNames":17},"without ECMO piperacillin","patients in intensive care without ECMO with antiinfective therapy : piperacillin",[13],[19],{"type":6,"name":20,"description":10,"armGroupLabels":21,"otherNames":10},"blood sample",[9,15],[23],{"name":24,"affiliation":5,"role":25},"Pierre Fillatre","PRINCIPAL_INVESTIGATOR",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"CHU Rennes","Rennes","France","FR",{"type":33,"coordinates":34},"Point",[35,36],-1.67431,48.11109,{"lat":36,"lon":35},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100279446","ec-motion--extracorporeal-membrane-oxygenation-and-therapeutic-drug-monitoring-of-drugs-of-infection-100279446",false,"NCT02917486","EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION","EC-MOTION","Inclusion Criteria:\n\n* Age over 18 years\n* Hospitalisation in intensive care\n* Treatment with ECMO or without ECMO\n* Introducing sepsis treated with an anti-infective molecule studied (piperacillin) for less than 48 hours\n* With an arterial catheter\n* Patient Information or their next of kin according to the patients status.\n\nExclusion Criteria:\n\n* Pregnancy\n* Major person under legal protection (backup justice, trusteeship, quardianship), person deprived of liberty","ALL","18 Years",{"count":50,"type":51},44,"ACTUAL","OBSERVATIONAL","The objective of the study is to investigate the exposure difference between antibiotic studied patients in intensive care with Extracorporeal Membrane Oxygenation and patients without Extracorporeal Membrane Oxygenation.\n\nThe exhibition is evaluated by population pharmacokinetic modeling.",[55],"Infection",[57,58,59],"ExtraCorporeal Membrane Oxygenation","patient in intensive care","pharmacokinetic modeling","COMPLETED","2026-06-11",{"date":63,"type":51},"2026-06-12",{"date":65,"type":51},"2016-01",{"date":67,"type":51},"2019-07",{"name":5,"class":6},1]